Froben Throat Mouthwash 160 ml

Froben Gola is used in the symptomatic treatment of irritative-inflammatory states also associated with pain in the oropharyngeal cavity (eg gingivitis, stomatitis, pharyngitis), also as a consequence of conservative or extractive dental therapy.

Dosage and method of use
The recommended dose of Froben Gola is two or three rinses or gargles a day with 10ml of mouthwash. It can be diluted in water.

Contraindications

Flurbiprofen is contraindicated in patients with known hypersensitivity (asthma, urticaria or allergic type) to flurbiprofen or to any of the excipients, and to aspirin or other NSAIDs.
Flurbiprofen is also contraindicated in patients with a history of gastrointestinal bleeding or perforation related to previous NSAID treatment.
Flurbiprofen should not be taken by patients with active or anamnestic ulcerative colitis, Crohn's disease, recurrent peptic ulcer or gastrointestinal bleeding (defined as two or more distinct episodes of proven ulceration or bleeding).
Flurbiprofen is contraindicated in patients with severe heart failure.
Third trimester of pregnancy
Special warnings
The use of Froben Gola, especially if prolonged, can give rise to sensitization phenomena or local irritation; in such cases it is necessary to interrupt the treatment and consult the doctor to establish, if necessary, a suitable therapy. Do not use for prolonged treatments. After short periods of treatment without appreciable results, consult your doctor. Both the mouthwash and the oral mucosal spray contain para-hydroxybenzoates which can cause allergic reactions (possibly delayed).

Both the mouthwash and the spray contain ethyl alcohol. For those who carry out sports activities, the use of medicines containing ethyl alcohol can determine a positive doping test in relation to the alcohol concentration limits indicated by some sports federations.

Pregnancy and breastfeeding

Pregnancy
Inhibition of prostaglandin synthesis can adversely affect pregnancy and / or embryo / fetal development. Results of epidemiological studies suggest an increased risk of miscarriage and cardiac malformation and gastroschisis after use of a prostaglandin synthesis inhibitor in early pregnancy. The absolute risk of cardiac malformations increased from less than 1% to approximately 1.5%. The risk was believed to increase with dose and duration of therapy. In animals, administration of prostaglandin synthesis inhibitors has been shown to cause an increase in pre- and post-implantation loss and embryo-fetal mortality.

In addition, an increased incidence of various malformations, including cardiovascular, has been reported in animals given prostaglandin synthesis inhibitors during the organogenetic period. During the first and second trimester of pregnancy, flurbiprofen should not be administered except in strictly necessary cases. If flurbiprofen is used by a woman attempting to conceive or during the first and second trimester of pregnancy, the dose and duration of treatment should be kept as low as possible.

During the third trimester of pregnancy, all prostaglandin synthesis inhibitors can expose the fetus to:

Cardiopulmonary toxicity (with premature closure of the arterial duct and pulmonary hypertension);
Renal dysfunction, which can progress to renal failure with oligohydroamnios;

The mother and the newborn, at the end of pregnancy, may be exposed to:

Possible prolongation of bleeding time, an antiplatelet effect that can occur even at very low doses;
Inhibition of uterine contractions resulting in delayed or prolonged labor.
Consequently flurbiprofen is contraindicated during the third trimester of pregnancy.

Feeding time
Flurbiprofen is excreted in breast milk; however the amount excreted is only a small fraction of the maternal dose. Administration of flurbiprofen is not recommended in nursing mothers.

Expiry and retention
Check the expiration date indicated on the package. The expiry date indicated on the package refers to the product in intact packaging, correctly stored. Store at a temperature not exceeding 25 ° C.

Warning: do not use the medicine after the expiry date indicated on the package.